Brokers Issue Forecasts for VYGR FY2029 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Research analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Voyager Therapeutics in a research note issued to investors on Tuesday, February 11th. Wedbush analyst Y. Zhong anticipates that the company will post earnings per share of ($0.86) for the year. Wedbush has a “Outperform” rating and a $9.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter last year, the business earned ($0.59) EPS.

Other analysts also recently issued research reports about the stock. Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $5.73 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Monday, January 27th. Citigroup started coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Finally, StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $15.72.

Voyager Therapeutics Stock Performance

VYGR stock opened at $4.38 on Thursday. Voyager Therapeutics has a 52 week low of $4.00 and a 52 week high of $10.66. The company has a market capitalization of $239.28 million, a PE ratio of 6.17 and a beta of 0.91. The company’s 50-day simple moving average is $5.65 and its 200 day simple moving average is $6.32.

Institutional Trading of Voyager Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Hunter Perkins Capital Management LLC raised its position in Voyager Therapeutics by 3.3% in the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after purchasing an additional 2,025 shares during the last quarter. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Voyager Therapeutics by 7.0% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 136,894 shares of the company’s stock valued at $801,000 after buying an additional 9,000 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares during the last quarter. Empowered Funds LLC boosted its position in Voyager Therapeutics by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after buying an additional 2,278 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Voyager Therapeutics during the 3rd quarter worth approximately $74,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 10,778 shares of company stock valued at $58,548. Corporate insiders own 4.53% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.